UniProt ID | MK13_HUMAN | |
---|---|---|
UniProt AC | O15264 | |
Protein Name | Mitogen-activated protein kinase 13 | |
Gene Name | MAPK13 | |
Organism | Homo sapiens (Human). | |
Sequence Length | 365 | |
Subcellular Localization | ||
Protein Description | Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK13 is one of the four p38 MAPKs which play an important role in the cascades of cellular responses evoked by extracellular stimuli such as proinflammatory cytokines or physical stress leading to direct activation of transcription factors such as ELK1 and ATF2. Accordingly, p38 MAPKs phosphorylate a broad range of proteins and it has been estimated that they may have approximately 200 to 300 substrates each. MAPK13 is one of the less studied p38 MAPK isoforms. Some of the targets are downstream kinases such as MAPKAPK2, which are activated through phosphorylation and further phosphorylate additional targets. Plays a role in the regulation of protein translation by phosphorylating and inactivating EEF2K. Involved in cytoskeletal remodeling through phosphorylation of MAPT and STMN1. Mediates UV irradiation induced up-regulation of the gene expression of CXCL14. Plays an important role in the regulation of epidermal keratinocyte differentiation, apoptosis and skin tumor development. Phosphorylates the transcriptional activator MYB in response to stress which leads to rapid MYB degradation via a proteasome-dependent pathway. MAPK13 also phosphorylates and down-regulates PRKD1 during regulation of insulin secretion in pancreatic beta cells.. | |
Protein Sequence | MSLIRKKGFYKQDVNKTAWELPKTYVSPTHVGSGAYGSVCSAIDKRSGEKVAIKKLSRPFQSEIFAKRAYRELLLLKHMQHENVIGLLDVFTPASSLRNFYDFYLVMPFMQTDLQKIMGMEFSEEKIQYLVYQMLKGLKYIHSAGVVHRDLKPGNLAVNEDCELKILDFGLARHADAEMTGYVVTRWYRAPEVILSWMHYNQTVDIWSVGCIMAEMLTGKTLFKGKDYLDQLTQILKVTGVPGTEFVQKLNDKAAKSYIQSLPQTPRKDFTQLFPRASPQAADLLEKMLELDVDKRLTAAQALTHPFFEPFRDPEEETEAQQPFDDSLEHEKLTVDEWKQHIYKEIVNFSPIARKDSRRRSGMKL | |
Overview of Protein Modification Sites with Functional and Structural Information | ||
|
* ASA = Accessible Surface Area
Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
---|---|---|---|---|---|
2 | Phosphorylation | ------MSLIRKKGF ------CCCHHCCCC | 32.29 | 24719451 | |
10 | Phosphorylation | LIRKKGFYKQDVNKT CHHCCCCCCCCCCCC | 19.19 | - | |
24 | Phosphorylation | TAWELPKTYVSPTHV CHHHCCCCEECCCCC | 27.50 | 23312004 | |
25 | Phosphorylation | AWELPKTYVSPTHVG HHHCCCCEECCCCCC | 12.69 | 23312004 | |
27 | Phosphorylation | ELPKTYVSPTHVGSG HCCCCEECCCCCCCC | 17.42 | 24719451 | |
29 | Phosphorylation | PKTYVSPTHVGSGAY CCCEECCCCCCCCCC | 22.99 | 28348404 | |
33 | Phosphorylation | VSPTHVGSGAYGSVC ECCCCCCCCCCHHHH | 21.11 | 23312004 | |
36 | Phosphorylation | THVGSGAYGSVCSAI CCCCCCCCHHHHHHH | 17.29 | 23312004 | |
38 | Phosphorylation | VGSGAYGSVCSAIDK CCCCCCHHHHHHHHC | 13.79 | 23312004 | |
47 | Phosphorylation | CSAIDKRSGEKVAIK HHHHHCCCCCEEEEE | 57.98 | 22817900 | |
123 | Phosphorylation | KIMGMEFSEEKIQYL HHHCCCCCHHHHHHH | 31.38 | 29116813 | |
129 | Phosphorylation | FSEEKIQYLVYQMLK CCHHHHHHHHHHHHH | 11.12 | 29116813 | |
143 | Phosphorylation | KGLKYIHSAGVVHRD HCCCHHHHCCEECCC | 19.70 | - | |
180 | Phosphorylation | RHADAEMTGYVVTRW HHCCHHHCCEEEEEE | 19.50 | 27273156 | |
182 | Phosphorylation | ADAEMTGYVVTRWYR CCHHHCCEEEEEEEE | 5.20 | 27273156 | |
185 | Phosphorylation | EMTGYVVTRWYRAPE HHCCEEEEEEEECCH | 12.87 | 23927012 | |
226 | Ubiquitination | GKTLFKGKDYLDQLT CCCCCCCHHHHHHHH | 43.73 | 21906983 | |
261 | Phosphorylation | AAKSYIQSLPQTPRK HHHHHHHCCCCCCCC | 32.24 | 27251275 | |
265 | Phosphorylation | YIQSLPQTPRKDFTQ HHHCCCCCCCCCHHH | 24.11 | 29496963 | |
350 | Phosphorylation | YKEIVNFSPIARKDS HHHHHCCCCCCCCHH | 15.36 | 22617229 | |
357 | Phosphorylation | SPIARKDSRRRSGMK CCCCCCHHCHHCCCC | 30.62 | - | |
361 | Phosphorylation | RKDSRRRSGMKL--- CCHHCHHCCCCC--- | 41.23 | - |
Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
---|---|---|---|---|---|---|
180 | T | Phosphorylation | Kinase | MKK3 | P46734 | PSP |
180 | T | Phosphorylation | Kinase | MAP2K4 | P45985 | Uniprot |
180 | T | Phosphorylation | Kinase | MKK6 | P52564 | PSP |
180 | T | Phosphorylation | Kinase | MAP2K7 | O14733 | Uniprot |
182 | Y | Phosphorylation | Kinase | MKK3 | P46734 | PSP |
182 | Y | Phosphorylation | Kinase | MAP2K4 | P45985 | Uniprot |
182 | Y | Phosphorylation | Kinase | MKK6 | P52564 | PSP |
182 | Y | Phosphorylation | Kinase | MAP2K7 | O14733 | Uniprot |
Modified Location | Modified Residue | Modification | Function | Reference |
---|---|---|---|---|
180 | T | Phosphorylation |
| 9374491 |
* Distance = the distance between SAP position and PTM sites.
Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of MK13_HUMAN !! |
Interacting Protein | Gene Name | Interaction Type | PPI Reference | Domain-Domain Interactions |
---|---|---|---|---|
ATF2_HUMAN | ATF2 | physical | 12244047 | |
FGF12_HUMAN | FGF12 | physical | 12244047 | |
AKIP1_HUMAN | AKIP1 | physical | 18624398 | |
ANKL2_HUMAN | ANKLE2 | physical | 18624398 | |
MBP_HUMAN | MBP | physical | 17906618 | |
HTRA2_HUMAN | HTRA2 | physical | 17906618 | |
A4_HUMAN | APP | physical | 21832049 | |
TAU_HUMAN | MAPT | physical | 9199504 | |
POTEF_HUMAN | POTEF | physical | 26186194 | |
M3K4_HUMAN | MAP3K4 | physical | 25241761 | |
MAPK3_HUMAN | MAPKAPK3 | physical | 25241761 | |
SQSTM_HUMAN | SQSTM1 | physical | 26279575 | |
POTEF_HUMAN | POTEF | physical | 28514442 |
Kegg Disease | ||||||
---|---|---|---|---|---|---|
There are no disease associations of PTM sites. | ||||||
OMIM Disease | ||||||
There are no disease associations of PTM sites. | ||||||
Kegg Drug | ||||||
There are no disease associations of PTM sites. | ||||||
DrugBank | ||||||
There are no disease associations of PTM sites. |
loading...
Phosphorylation | |
Reference | PubMed |
"Large-scale proteomics analysis of the human kinome."; Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,Mann M., Daub H.; Mol. Cell. Proteomics 8:1751-1764(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-350, AND MASSSPECTROMETRY. | |
"Phosphoproteome of resting human platelets."; Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,Schuetz C., Walter U., Gambaryan S., Sickmann A.; J. Proteome Res. 7:526-534(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-47, AND MASSSPECTROMETRY. | |
"Characterization of the structure and function of the fourth memberof p38 group mitogen-activated protein kinases, p38delta."; Jiang Y., Gram H., Zhao M., New L., Gu J., Feng L., Di Padova F.,Ulevitch R.J., Han J.; J. Biol. Chem. 272:30122-30128(1997). Cited for: NUCLEOTIDE SEQUENCE [MRNA], PHOSPHORYLATION AT THR-180 AND TYR-182,MUTAGENESIS OF THR-180 AND TYR-182, ENZYME REGULATION, AND TISSUESPECIFICITY. | |
"Global survey of phosphotyrosine signaling identifies oncogenickinases in lung cancer."; Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., Nardone J.,Lee K., Reeves C., Li Y., Hu Y., Tan Z., Stokes M., Sullivan L.,Mitchell J., Wetzel R., Macneill J., Ren J.M., Yuan J.,Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D., Zhou X.,Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.; Cell 131:1190-1203(2007). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-182, AND MASSSPECTROMETRY. |